PFC, Tech Mahindra and Dr. Reddy's to see some action today

Dr. Reddys Laboratories Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 500124 | NSE: DRREDDY

12 Mar 2021 Evaluate

Power Finance Corporation (PFC) and REC have entered into a pact with Bhutan-based Kholongchhu Hydro Energy (KHEL) to finance a 600-megawatt hydroelectric project at Trashiyangtse in the neighbouring country. KHEL is a 50:50 joint venture between SJVN India and Druk Green Power Corporation (Bhutan) set up for developing the 600-MW Kholongchhu hydroelectric project in the eastern Bhutan.

Tech Mahindra has achieved System and Organization Control (SOC) 2 Type 2 attestation for BPS and IT services. The SOC 2 report reinforces Tech Mahindra’s commitment towards safeguarding customers security, privacy, availability and confidentiality across all services globally. Tech Mahindra continues to demonstrate its focus on customer trust, loyalty and quality in business operations.

Dr. Reddy's Laboratories’ API manufacturing plant at New York has received three observations from United States Food and Drug Administration (USFDA). The audit of API manufacturing plant at Middleburg, New York has been completed by the USFDA. The company will address three observations comprehensively within the stipulated timeline. Currently, the company does not have any sales from this plant.

Sun Pharmaceutical Industries’ one of the wholly owned subsidiaries has acquired 428,571 ordinary shares (equivalent to 12.5% fully diluted equity stake) of WRS Bioproducts Pty. by making the payment of Australian dollar (AUD) 2.0 million and complying with all requirements.

NBCC (India) has executed Memorandum of Understanding (MoU) with National Institute of Technology, Patna for supervision of construction & development of institute campus, hostel and residential buildings, etc. at NIT Patna (Bihta Campus). NBCC is the Project Management Consultant for this project of value Rs 468 crore approximately.

Prestige Estates Projects has completed phase 1 of proposed transaction with Blackstone Group. The enterprise value forming part of phase 1 is approximately Rs 74,670 million out of the total enterprise value of approximately Rs 91,600 Million. Phase 1 of the transaction includes sale of twelve assets/undertakings comprising of completed retail, office and hotel assets. Phase 2 of the transaction is expected to get completed by the end of next Quarter.

Karur Vysya Bank and Cholamandalam Investment and Finance Company (Chola), the financial services arm of the Murugappa Group, have successfully launched Co-lending business in partnership. The co-lending model is a great opportunity for banks and NBFCs to draw upon each other’s strengths.

Dr. Reddys Lab Share Price

1293.25 -13.55 (-1.04%)

08-May-2026 16:59 View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1847.30
Dr. Reddys Lab	1293.25
Cipla	1347.70
Zydus Lifesciences	938.90
Lupin	2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.